ImmuLogic Pharmaceutical Corp. took two steps forward in its relations with the FDA, and two steps back in the timeline for development of its Allervax Cat peptide for cat allergy.

Based on its Dec. 19 meeting with the agency, the company last week said that it will begin a new study of Allervax Cat in the second quarter of 1997, to be followed by a larger study, prior to a PLA filing. The first trial probably will take about six months, though it might last longer if IMUL decides to look at long-term effects of its compound in patients with chronic asthma. Those patients will be among a variety of patients the company plans to enroll in the new trial, according to Acting President and CEO Joseph Marr.